Investigator’s Brochure: BNT162/PF-07302048

BioNTech RNA Pharmaceuticals GmbH

The development of a ribonucleic acid (RNA)-based vaccine encoding a viral antigen that is translated by the vaccinated organism to protein to induce a protective immune response provides significant advantages over more conventional vaccine approaches.

At BioNTech, there are three different RNA platforms under development, namely non- modified uridine containing mRNA (uRNA), nucleoside modified mRNA (modRNA), and self-amplifying mRNA (saRNA).

BNT162 vaccine candidates based on the uRNA, modRNA, and saRNA formats are currently under investigation in three clinical trials with healthy adults (men and women) aged between 18 and 85 yrs.

Latest articles

The Goddard Report A podcast with Dr. Stephen Malthouse on “Making Doctors... All previous outbreaks, epidemics and pandemics end when Community Immunity, NOT...
Amanuensis Variants have been one of the hallmarks of this pandemic, with...
Samuel Reinfeld et al. The COVID-19 pandemic continues to have a deleterious...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!